- Supplementary Content
- 10.2139/ssrn.6072409
The Mind-Body-Meaning Integrative Health Conceptual Model: A Clinician-Led Approach to Human-Centered, Whole-Person Care
- Jan 01, 2026
- SSRN Electronic Journal
- Oniel Laucella
Publications from 2021 to 2026
Showing 10 of 40 papers
The Mind-Body-Meaning Integrative Health Conceptual Model: A Clinician-Led Approach to Human-Centered, Whole-Person Care
Educator's Implementation and Understanding of Translanguaging and Universal Design for Learning in Teaching Culturally Responsive Computer Science Education
This paper describes responses from a teacher survey related to the implementation of Culturally Responsive-Sustaining Education (CR-SE) practices in New York City's Computer Science for All (CS4All) initiative. The research questions investigate educators' attitudes and beliefs regarding CR-SE, their approaches to integrating CR-SE practices into computer science instruction, and the challenges encountered during the implementation of these practices. We conducted a content analysis of open-ended survey responses of middle and high school teachers about their understanding of practices related to Universal Design for Learning (UDL) and translanguaging.
Read moreFunctional connectivity for white-tailed deer drives the distribution of tick-borne pathogens in a highly urbanized setting
ContextAs cities seek to provide more habitat for wildlife, there may be unintended consequences of increasing tick-borne disease hazards. In the United States, the Northeast is both highly urban and a hotspot for blacklegged ticks (Ixodes scapularis) and tick-borne disease emergence. Though tick-borne disease was once considered a suburban and rural problem, tick-borne hazards in urban landscapes are increasing.ObjectivesWe hypothesized that multi-scale ecological processes hierarchically contribute to tick-borne hazards across an urbanization gradient. Urban greenspaces with higher functional connectivity to deer movement would have higher deer occupancy at the ‘ecological neighborhood’ scale, resulting in increased blacklegged tick populations and pathogen infection at the scale of within greenspaces.MethodsTo evaluate our hypothesis, we used circuit theory methods to model the impact of functional connectivity on deer occupancy, blacklegged tick abundance, and pathogen infected ticks across an urbanization gradient. We sampled nymphal ticks during their peak activity and deployed wildlife cameras to detect deer at 38 greenspaces across New York City and Long Island, NY from 2022 to 2023.ResultsWe found that functional connectivity significantly predicted deer occupancy with cascading effects on abundance of blacklegged nymphal ticks and Borrelia burgdorferi infection. We novelly identified a threshold of functional connectivity in urban areas necessary for deer occupancy, tick populations, and tick infection with B. burgdorferi, to emerge in urban environments.ConclusionsWe recommend targeted tick-borne hazard mitigation along this functional connectivity threshold as part of urban greenspace management plans. Additionally, we highlight the importance of examining multi-scale landscape drivers of host, tick, and pathogen interactions.
Read moreHope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast Cancer
Breast cancer affects 1/8 of women throughout their lifetimes, with over 90% of cancer deaths being caused by metastasis. However, metastasis poses unique challenges to research, as complex changes in the microenvironment in different metastatic sites and difficulty obtaining tissue for study hinder the ability to examine in depth the changes that occur during metastasis. Rapid autopsy programs thus fill a unique need in advancing metastasis research. Here, we describe our protocol and processes for establishing and improving the US-based Hope for OTHERS (Our Tissue Helping Enhance Research and Science) program for organ donation in metastatic breast cancer. As of August 2024, we consented 114 patients and performed 37 autopsies, from which we collected 551 unique metastatic frozen tumor samples, 1244 FFPE blocks, 90 longitudinal liquid biopsy samples and developed 14 patient-derived organoid and 8 patient-derived xenograft models. We report in-depth clinical and histopathological information and discuss extensive new research and novel findings in patient outcomes, metastatic phylogeny, and factors in successful living model development. Our results reveal key logistical and protocol improvements that are uniquely beneficial to certain programs based on identifiable features, such as working closely with patient advocates, methods to rescue RNA quality in cases where tissue quality may degrade due to time delays, as well as guidelines and future expansions of our program.
Read moreIntegrative Eco Art Therapy: Addressing Humanity’s Fractured Attachment to Nature
Integrative Eco Art Therapy (IEAT) is a humanistic and eco-centric approach to restoring and cultivating healthy attachments between humans and the natural world. IEAT employs the frameworks of art therapy, eco art therapy, integrative trauma-informed psychology, and the sciences, to provide individually centered healing that is informed by the principles of Interbeing, reciprocity, and cooperation. This article presents both a theoretical framework for IEAT and an in-depth case study of IEAT with a young adult with complex trauma and maladaptive daydreaming disorder. A distinct link was observed between the creation of art in or with Nature within an IEAT framework, and the improvement of this individual’s executive functioning, integration of traumatic experience, and establishment of more secure attachments. Through integrative didactic engagement, experientially gained insight, artmaking in which Nature serves as metaphor, material, or setting, IEAT can restore and repair some of the fractured attachments humans have to themselves, other people, and the natural world.
Read moreExperience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan
SUMMARYBACKGROUNDPakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter, all-oral, well-tolerated and more effective treatment.METHODSWe conducted a retrospective cohort study to pilot the BPaLM/BPaL regimen at four selected sites in two provinces of Pakistan, i.e. Punjab and Khyber Pakhtunkhwa. Data were extracted and analysed using electronic medical records from the program. Descriptive statistics, survival analysis and binary logistic regression analysis were employed.RESULTSA total of 116 patients took treatment between October 2022 and February 2023. The treatment success rate was 96%, with 3% deaths and <1% loss to follow-up. Patients typically completed treatment in 26.2–26.7 weeks for BPaLM and BPaL, respectively. No serious adverse events were observed. The most common side effects included QTcF prolongation (BPaLM: 55%, BPaL: 84%), haematological events (BPaLM: 32%, BPaL: 34%), and gastrointestinal problems (BPaLM: 36%, BPaL: 25%).CONCLUSIONThe BPaLM/BPaL regimens for DR-TB are highly effective with minimal adverse events and feasible to implement in routine program circumstances.
Read moreDose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
TBI-223, a novel oxazolidinone for tuberculosis, is designed to provide improved efficacy and safety compared to linezolid in combination with bedaquiline and pretomanid (BPaL). We aim to optimize the dosing of TBI-223 within the BPaL regimen for enhanced therapeutic outcomes. TBI-223 is investigated in preclinical monotherapy, multidrug therapy, and lesion penetration experiments to describe its efficacy and safety versus linezolid. A translational platform incorporating linezolid and BPaL data from preclinical experiments and 4 clinical trials (NCT00396084, NCT02333799, NCT03086486, NCT00816426) is developed, enabling validation of the framework. TBI-223 preclinical and Phase 1 data (NCT03758612) are applied to the translational framework to predict clinical outcomes and optimize TBI-223 dosing in combination with bedaquiline and pretomanid. Results indicate that daily doses of 1200–2400 mg TBI-223 may achieve efficacy comparable to the BPaL regimen, with >90% of patients predicted to reach culture conversion by two months.
Read moreSavings from the introduction of BPaL and BPaLM regimens at the country level
SUMMARYBACKGROUNDIn 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM.METHODOLOGYCountry data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes. Where BPaL/BPaLM is not currently used, clinical trial outcomes data are used to estimate cost-effectiveness. DALYs are calculated using the Global Burden of Disease (GBD) database.RESULTSWe present the results of four countries that have used the tool and shared their data. When shorter and longer regimens are replaced with BPaL/BPaLM, the savings per patient treated in Pakistan, the Philippines, South Africa, and Ukraine are $746, $478, $757, and $2,636, respectively. An increased number of patients would be successfully treated with BPaL/BPaLM regimens, with 411, 1,025, 1,371 and 829 lives saved and 20,179, 27,443, 33,384 and 21,924 DALYs averted annually in the four countries, respectively.CONCLUSIONThrough BPaL/BPaLM regimens, drug-resistant TB treatment has become more effective, shorter, less burdensome for patients, cheaper for both health systems and patients, and saves more lives.
Read moreDevelopment, implementation, and evaluation of an innovative clinical trial operations training program for Africa (ClinOps)
Abstract Background Africa's involvement in clinical trials remains very low. Although the crucial role of training initiatives in building clinical trial capacity in Africa has been documented, current efforts fall short as they lack alignment with local contexts. This study aimed to design, develop, implement, and evaluate an innovative clinical trial operations training program for Africa. Methods We developed ClinOps, a novel 10-week clinical trial operations training program for study coordinators in Africa, intending to enhance their expertise in four fundamental areas: designing, conducting, managing, and reporting clinical trials. We used cloud applications to minimize installation of software, whilst maximizing student engagement with the course, VoiceThread, an interactive collaboration and sharing tool allowed interactive content to be accessed offline. Moodle, an open-source learning management system provided a platform to share learning tools, provide one-on-one mentorship, and multidirectional competency assessment strategies including lesson quizzes, forum discussions, asynchronous tutorials, and group assignments. We used Zoom video conferencing application for live tutorials and mentoring, as required. Program effectiveness was evaluated through quantitative pre-post tests, qualitative end-course evaluations, and a comprehensive monitoring and evaluation. We used Wilcoxon rank test to compare pre-post test scores and thematic analysis to analyze the qualitative data. Results In the initial cohort, 88 study coordinators from 19 countries participated, including 56 (64%) females, with 57 (65%) actively employed as study coordinators during the training, and 85 (97%) possessing prior experience in clinical trial roles. Among these, 71 (81%) successfully completed the course, with 69 (97%) also completing the post-course assessment. Post-training scores demonstrated substantial improvement compared to pre-training scores in each competency area, including in designing (mean rank = 36.27 vs 12.20; Z = 6.799, p < 0.001), conducting (mean rank = 31.78 vs 8.0; Z = -6.68, p < 0.001), managing (mean rank = 36.89 vs 9.83; Z = -6.813, p < 0.001), and reporting (mean rank = 16.94 vs 3.0; Z = -4.897, p < 0.001) clinical trials. The program adhered to training best practices, encompassing alignment with local priorities, country ownership, pedagogic innovation, institutional capacity building, sustainability, and ongoing partnerships. Participants acknowledged the program for its structure, content, relevance to their current roles, and the overall delivery methods. Conclusion The ClinOps program, a clinical trial operations training initiative for Africa developed by experts from academia and product development partners, significantly enhanced participants' competency in clinical trials. Transferring the program to a local institution promoted country ownership and established the local partner institution as a sustainable clinical trial training hub for Africa. To effectively build clinical trials capacity in Africa, training initiatives should offer comprehensive competency in designing, conducting, managing, and reporting trials tailored to local contexts.
Read morePA-459 The effect on treatment outcomes of baseline resistance to pyrazinamide after 6-months of BPaMZ in the SimpliciTB clinical trial
BackgroundThe combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) provides the shortest duration of treatment required to sterilize mice in relapsing mouse models. SimpliciTB was an open-label study to evaluate the safety and efficacy of 4-months BPaMZ (4BPaMZ) compared to standard therapy (4HRZE/2HR) in DS-TB participants. The trial also included a cohort of DR-TB participants who received 6-months BPaMZ (6BPaMZ). The primary efficacy endpoint was time to culture negative status through 8 weeks; the key secondary endpoint was relapse-free cure at week 52. The proportions of patients with culture conversion by 8 weeks and of favorable outcome at week 52 (MITT analysis) for 4HRZE/2HR, 4BPaMZ and 6BPaMZ were 47.3%, 84.1%, 85.7% and 93.1%, 85.3%, 83.1%, respectively. The lower rates of favorable outcomes in BPaMZ arms were largely due to higher rates of hepatotoxicity-related trial discontinuations, in which PZA may have contributed.MethodsUsing Kaplan-Meier (KM) and Cox PH models adjusting for socio-demographic and clinical factors, we explored the effect on outcome of baseline resistance to pyrazinamide (BRZ) in the DR-TB group of participants.Results55 of 152 (36.2%) participants in the DR-TB cohort had BRZ based on phenotypic and genotypic drug susceptibility testing. Time to negative sputum culture for patients with and without BRZ was not statistically significantly different (aHR=0.79, 95% CI (0.54,1.15) p= 0.22). Relapse-free cure was documented in 42/51 (82%) participants with and 68/79 (86%) participants without BRZ (unadjusted Chi-sq test p=0.57). ConclusionPZA resistance at baseline did not impact outcomes at week 8 or week 52 in DR-TB patients treated with BPaMZ. A regimen of pretomanid, moxifloxacin with a potent diarylquinoline could present an efficacious and better tolerated therapeutic alternative for DS- and DR-TB patients and should also be explored as a therapeutic option for DS-TB.
Read more